TrialAmerican journal of ophthalmology2020

High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.

Natalie Wolkow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.